Skip to main content
  • Locate a Specialist

    Locate a Specialist

    ASCIA is the peak professional body
    of clinical immunology and allergy
    in Australia and New Zealand
    Search here
  • Anaphylaxis Resources

    Anaphylaxis Resources

    ASCIA is the peak professional body
    of clinical immunology and allergy
    in Australia and New Zealand
    Learn more
  • Immunodeficiency

    Immunodeficiency

    ASCIA is the peak professional body
    of clinical immunology and allergy
    in Australia and New Zealand
    Go to information
  • AIFA support research

    AIFA 100% Research

    All donations to AIFA go
    directly to clinical immunology
    and allergy research
    Donate now

ASCIA News

  • ATAGI COVID-19 vaccine recommendations 2023
    Monovalent COVID-19 Omicron XBB.1.5 vaccines are now available in Australia, following the Therapeutic Goods Administration of Australia (TGA) approval of the following XBB 1.5 vaccines for use as primary and additional doses: Pfizer monovalent Omicron XBB.1.5 vaccine 5 -...
  • ASCIA Update – Shared Care Project
    ASCIA’s involvement in the National Allergy Council Shared Care project includes: Advocacy to increase access to care, including food and drug challenges, to improve diagnosis and management of allergic conditions. Education, training and mentorship of health...
  • Changes to PBS Criteria - Jorveza EoE treatment
    Jorveza® (budesonide) is an orally disintegrating tablet for the treatment of eosinophilic oesophagitis (EoE) in adults, that was first listed on the Pharmaceutical Benefits Scheme (PBS) on 1 May 2022. Several changes have been made to PBS prescribing criteria (from 1...
  • ASCIA Food Allergy and Adverse Food Reactions Course for Dietitians in Sydney 23rd-24th November 2023
    Registration is now closed for the ASCIA Food Allergy and Adverse Food Reactions Course in Sydney, in Sydney 23rd-24th November 2023 The next course is scheduled for early May 2024 in Adelaide, South Australia. This course has an interactive in-person program that is...
  • Shingrix Vaccine to Prevent Shingles
    Shingrix®  is a varicella zoster virus recombinant vaccine that can provide protection from herpes zoster (shingles) and post-herpetic neuralgia (long-term nerve pain). Funding of Shingrix from 1 November 2023 was announced by the hon Mark Butler (Minister for Health and Aged...
  • Undergraduate Allergy Training for Health Professionals Survey
    People who are involved in the development and/or delivery of tertiary healthcare degrees in Australia are invited to complete a survey about allergy training. ASCIA is conducting this survey as part of the National Allergy Council Shared Care for Allergy Project. The survey...
  • ACECQA approved ASCIA anaphylaxis e-training for children's education and care services
    ASCIA anaphylaxis e-training for children's education and care services has been approved by the Australian Children's Education and Care Quality Authority (ACECQA) until October 2026.  The ASCIA course is now published on ACECQA’s approved anaphylaxis management course...
  • AusPollen partnership impact case study published by NHMRC
    An Impact Case Study on the AusPollen Partnership and associated research projects has recently been published by the NHMRC, the peak national body supporting health and medical research in Australia. Read more here The AusPollen partnership is an important research...
More ASCIA News
ASCIA Member Login
Site last updated: 26 Nov 2023
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...